Market Newsdesk

All amounts in U.S. dollars unless otherwise stated 

TORONTO, Dec. 30, 2020 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) today announced that it has acquired Falcon Investment Advisors, LLC (“Falcon”), a leading U.S. private credit manager, to expand its established credit platform and solidify its market position in tradeable, opportunistic and private credit.

Falcon provides private credit financing solutions and has US$3.8 billion of assets under management as of September 30, 2020. It employs an opportunistic approach to mezzanine and other direct lending investments for U.S. middle market companies. With this transaction, Onex Credit will have over $16 billion of alternative credit assets under management.

Falcon complements Onex Credit with a seasoned investment team, exceptional sourcing capabilities, strong fundraising and performance track record, and a long-standing institutional client base. The combined platform merges Falcon’s specialized private credit investing with the scale, global distribution and diverse investment and origination capabilities of Onex Credit and the broader Onex franchise. Falcon’s senior management team and employees are all joining the new platform within Onex Credit, called “Onex Falcon”. Current members of the Falcon investment team will continue to be responsible for the investments of existing and future funds, with the support of the Onex Credit platform and team.

“Falcon’s experienced team has a long track record of delivering strong returns,” said Jason New, Co-CEO of Onex Credit. “Sandeep Alva and his leadership and investment teams are field- and cycle-tested. We have created a differentiated and scalable private credit platform to compete with the best in our markets.”

Mr. Alva, Founder and Managing Partner of Falcon, said, “Over the last 20 years, we have earned our reputation as a creative, flexible credit manager in the U.S. middle market. Onex greatly enhances Falcon’s ability to develop a wider range of private credit portfolios, and thus fully leverage Falcon’s origination and deal structuring resources.”

“We look forward to building upon our existing alternative credit investment capabilities alongside such high-caliber partners,” added Blair Fleming, Managing Director at Onex Credit.

Mr. Fleming and several core members of the Onex private credit investment team are joining the Onex Falcon platform as the company looks to lever the strengths of each organization. Mr. Alva and Mr. Fleming will be Co-Business Heads reporting to Mr. New. Together, they will drive execution and strategy for the combined team.

Onex Credit has a successful 19-year track record executing a disciplined approach to credit investing with a focus on capital preservation and achieving strong risk adjusted returns through credit cycles. The Onex Credit team’s experience spans credit investing through its CLO platform and adjacent strategies, high yield bonds, opportunistic and structured credit, and middle market direct lending. Onex Credit’s mid-market to large cap focus and track record in credit are highly complementary with Falcon’s specialized focus in the lower middle market. Clients of both firms will benefit from the powerful combination, which creates enhanced scale and a broader origination network.

Advisors


Oppenheimer & Co. Inc. and Proskauer Rose LLP acted as financial advisor and legal counsel, respectively, to Falcon. Houlihan Lokey and Latham & Watkins LLP served as Onex Credit’s financial advisor and legal counsel, respectively.

About Onex Credit


Established in 2007, Onex Credit has grown its assets under management from approximately $300 million to over $16 billion, including the acquisition of Falcon. With offices in New York, New Jersey and London, Onex Credit’s business is focused on non-investment grade credit markets including leveraged loans, CLO, direct lending, high yield, and opportunistic investing strategies.

About Onex Corporation

Founded in 1984, Onex invests and manages capital on behalf of its shareholders, institutional investors and high net worth clients from around the world. Onex’ platforms include: Onex Partners, private equity funds focused on larger opportunities in North America and Europe; ONCAP, private equity funds focused on middle market and smaller opportunities in North America; Onex Credit, which manages primarily non-investment grade debt through collateralized loan obligations, senior loan strategies and other private credit strategies; and Gluskin Sheff’s wealth management services including its actively managed public equity and public credit funds. In total, as of September 30, 2020, Onex had approximately $36.6 billion of assets under management, of which approximately $6.7 billion is its own shareholder capital. With offices in Toronto, New York, New Jersey and London, Onex and its experienced management teams are collectively the largest investors across Onex’ platforms. The Onex Partners and ONCAP businesses have assets of $36 billion, generate annual revenues of $22 billion and employ approximately 149,000 people worldwide. Onex shares trade on the Toronto Stock Exchange under the stock symbol ONEX. For more information on Onex, visit its website at www.onex.com. Onex’ security filings can also be accessed at www.sedar.com.

About Falcon Investment Advisors, LLC


Headquartered in Boston, MA and with offices in New York, NY, Falcon is a private credit asset management firm which invests subordinated debt and non-controlling equity capital in leading middle market companies. Founded in 2000 and now with $3.8 billion of capital under management, Falcon specializes in structuring high-value private credit transactions and delivering differentiated portfolio exposures for its global client base. Falcon is currently investing out of its $1.3 billion Private Credit Opportunities Fund VI.

Forward-Looking Statements

This press release may contain, without limitation, statements concerning possible or assumed future operations, performance or results preceded by, followed by or that include words such as “believes”, “expects”, “potential”, “anticipates”, “estimates”, “intends”, “plans” and words of similar connotation, which would constitute forward-looking statements. Forward-looking statements are not guarantees. The reader should not place undue reliance on forward-looking statements and information because they involve significant and diverse risks and uncertainties that may cause actual operations, performance or results to be materially different from those indicated in these forward-looking statements. Except as may be required by Canadian securities law, Onex is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. These cautionary statements expressly qualify all forward-looking statements in this press release.

For Further Information

Jill Homenuk
Managing Director, Shareholder Relations and Communications
416.362.7711

IRVING, Texas, Dec. 30, 2020 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA), a location-agnostic global business process automation (BPA) leader, announced that it has retained UBS Investment Bank as an additional financial advisor to assist the Company and management in pursuing alternatives to strengthen its balance sheet and enhance shareholder value.  

The Company will make any future announcements related to this release as events dictate.

About Exela Technologies

Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of expertise operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune^® 100. With foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry department solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and public sectors. Through cloud-enabled platforms, built on a configurable stack of automation modules, and over 21,000 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.

Forward-Looking Statements
Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, estimated or anticipated future results and benefits, future opportunities for Exela, and other statements that are not historical facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties, including without limitation those discussed under the heading “Risk Factors” in Exela’s Annual Report and other securities filings. In addition, forward-looking statements provide Exela’s expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela’s assessments to change. These forward-looking statements should not be relied upon as representing Exela’s assessments as of any date subsequent to the date of this press release.

Investor and/or Media Contacts:
Vincent Kondaveeti
E: [email protected]
T: 929-620-1849

Mary Beth Benjamin
E: [email protected] 
T: 646-277-1216 

Vancouver, B.C., Dec. 30, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) is focused on the exploration and development of graphite for the new green economy.  Despite the negative effects of COVID, Lomiko Management are happy to report the company has made significant strides forward over the last year.

 2020 La Loutre Flake Graphite Property Developments

 Lomiko formed a La Loutre Technical, Safety and Sustainability Committee (“LTSSC”), reporting to the Board of Directors.  The LTSCC is comprised of A. Paul Gill, CEO and Directors, Gabriel Erdelyi and Gregg Jensen.  The LTSSC will oversee the assessment of the La Loutre Flake Graphite Property, and liaise with service providers, technical staff, and stakeholders to put forward a series of crucial technical documents including, but not limited to, a Scope of Work (SOW), Graphite Characterization and Metallurgy, Response for Proposal (RFP) on a Preliminary Economic Assessment, and, if required, pre-feasibility, bulk samples, pilot plant, feasibility and construction plans.  The Committee will govern the hiring of technical staff, liaise with extra-company agencies and representatives, and provide a conduit to the Board of Directors to make crucial decisions on the project.  The Board and Committee has accepted a proposal by SGS Canada Inc. to conduct a Metallurgical Process Development Program with results due in early 2021.

 

New Board Members

 

Mr. Mike Petrina joined the Lomiko Board and the Lomiko Technical, Safety and Sustainability Committee (“LTSSC”) has appointed him the Project Manager for development of La Loutre.  Mr. Petrina has years of executive experience with Adanac Molybdenum, Hawthorne Gold, MAG Silver and Probe Minerals.  Mr. Petrina’s extensive experience with advanced stage projects in the Pre-economic Assessment (PEA) Stage will be extremely helpful as Lomiko proceeds with the La Loutre Project.

 

Also, Mr. Gregg Jensen joined the Lomiko Board.  He has over 25 years of experience in Finance and Business management spanning several industries from technology, mining, engineering, to professional services.

 

Kenmar Securities Engaged to Raise $ 40 Million Cdn

 

Lomiko Metals engaged Kenmar Securities, LLC of New York to raise $ 40 million Cdn for the acquisition and development of critical metals projects. Kenmar Securities, LLC, is a Delaware limited liability corporation and SEC registered securities broker dealer and FINRA member.

 

The Advisor will assist the Company in analyzing its business, operations, properties, financial condition and prospects, prepare suitable marketing materials, contact any potential partner companies, assist and advise the Company with respect to the financial form and structure of any potential transaction.

 

Government Support for Critical Minerals Supply Chain Development

 

Lomiko has been monitoring emerging legislation aimed at reducing dependence on Chinese supply of graphite, lithium and other electric vehicle battery materials.  100% of graphite is currently imported to the United States as there is no domestic graphite mines able to produce material for graphite anodes used in Electric Vehicles.  Please also refer to news release September 9, 2020 and October, 7 2020 related to changing government policies regarding critical minerals.

 

US Election Bonus for Critical Minerals Companies

 

In a boon for the critical minerals mining industry, President-elect Joe Biden’s committed to a historic investment in clean energy and innovation, developing rigorous new fuel economy standards aimed at ensuring 100% of new sales for light- and medium-duty vehicles will be zero emissions and annual improvements for heavy duty vehicles.

 

Biden will invest $400 billion over ten years, as one part of a broad mobilization of public investment, in clean energy and innovation.  The funds will accelerate the deployment of clean technology throughout the US with a target of reducing the carbon footprint of the U.S. building stock 50% by 2035.  The new government will work with governors and mayors to support the deployment of more than 500,000 new public charging outlets by the end of 2030.

 

Lomiko’s Opportunity in the Critical Minerals Supply Chain

 

Graphite demand is expected to increase exponentially for natural graphite material, as more is used in the production of spherical graphite for graphite anodes of Electric Vehicle Lithium-ion batteries.

 

With a completion of $ 750,000 financing October 23, 2020, and a further $985,000 completed December 22, 2020, Lomiko plans to work on its near-term goals of the company are as follows:

 

1) Complete 100% Acquisition of the La Loutre Property, currently 80% owned by Lomiko Metals.

 

2) Complete metallurgy and graphite characterization to confirm li-ion anode grade material.

 

3) Complete a Technical Report to confirm the extent of the mineralization equals or surpasses the nearby Imerys Mine, owned by international mining conglomerate.

 

A “technical report” means a report prepared and filed in accordance with this Instrument and Form 43-101F1 Technical Report, and includes, in summary form, all material scientific and technical information in respect of the subject property as of the effective date of the technical report;

 

4) Complete Preliminary Economic Assessment (PEA)

 

A PEA means a study, other than a pre-feasibility or feasibility study, that includes an economic analysis of the potential viability of mineral resources.

 

For more information on Lomiko Metals, Promethieus, review the website at www.lomiko.com, and www.promethieus.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

 

On Behalf of the Board

 

“A. Paul Gill”

 

Director, Chief Executive Officer

 

We seek safe harbor.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accept responsibility for the adequacy or accuracy of this release.

 

Attachment

• Lomiko 1 -50+80 P2

A. Paul Gill
Lomiko Metals Inc. (TSX-V: LMR)
6047295312
[email protected]

Miami, Florida, Dec. 30, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Energy and Water Development Corp. (OTCQB: EAWD), a green-tech engineering solutions company focused on delivering Self Sufficient Energy Powered Water Generation Systems, is pleased to announce its uplifting to the OTCQB Venture Market (OTCQB) since December 21st, 2020.  

“We are excited about EAWD upgrade to the OTCQB Venture Market. This milestone exhibits our continued commitment to our shareholders; we believe listing on the OTCQB will provide the Company with increased access to US institutional and retail investors and a broader shareholder base. U.S. investors will have the opportunity to share in the Company’s growth, as investor interest in green tech solutions benefits of water generation gain momentum; U.S. investors can find Real-Time quotes and market information for EAWD at www.otcmarkets.com and access current company news and developments,” Ralph Hofmeier, Chief Executive Officer of Energy And Water Development Corp., stated.

The OTCQB offers transparent trading in entrepreneurial and development stage companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

About Energy and Water Development Corp.

Energy and Water Development Corp. (“EAWD”) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The Company offers design, construction, maintenance, and specialty consulting services to private companies, government entities and non-government organizations (NGOs).  EAWD builds water and energy systems out of already-existing, proven technologies, utilizing their technical know-how to customize solutions to their clients’ needs.

The Company’s website is: www.eawctechnologies.com

Forward-Looking Statements

This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings.

Contact Information:

Energy and Water Development Corp. 

Irma Velazquez, Chief Operating Officer 

Email: [email protected]

Tel. +1 347 871 8927

VANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) — Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”) is pleased to report it received a Biological Baseline Report for the Company’s Clayton Valley Lithium Project. The report was prepared by consultants, Stantec Consulting Services Inc. of Reno, Nevada, and documents biological surveys conducted during 2020. The work was conducted in the course of environmental due diligence studies at the Project. The data will aid in the design of a feasibility-level plan-of-operations (POO) for the Project in coordination with the National Environmental Policy Act process to support an Environmental Assessment or Environmental Impact Statement. The 183-page report includes a habitat evaluation for the approximately 5,500-acre survey area, baseline survey methodologies and biological findings including any species of concern.

Survey Area and Results

The biological survey area comprises the proposed Project disturbance as outlined in the Company’s May 2020 Prefeasibility Study (“PFS”) and covers about 5,500 acres of Cypress’ contiguous property around the project site. 

Stantec performed the biological surveys for vegetation and wildlife in the spring, summer, and fall of 2020. Wildlife study included aerial golden eagle and raptor surveys to identify nest sites and activity within 10 miles of the Project, and local small mammal and bat surveys. The flora surveys included vegetation community and soils mapping. In the surveys, no threatened or endangered species were found. Several special status species were observed which may result in modifications in the POO as configured in the PFS or steps to mitigate any potential impacts as the Project moves forward.

“While no threatened or endangered species were found, mining by nature has a direct impact on the immediate and surrounding environment,” said Cypress CEO Bill Willoughby. “Cypress believes responsible and effective environmental management is an integral part of project development. The information in this report allows us to proceed with our pilot plant program and will provide important information for permitting as Cypress moves the project towards a feasibility study and our goal for future production.”

In other News

Couloir Capital Initiates Research Coverage on Cypress Development:


Cypress Development Corp. (TSXV: CYP) – PFS Lithium Asset with Robust Economics and Strong Offtake Potential

About Cypress Development Corp.:

Cypress Development Corp. is a publicly traded exploration company focused on developing the Company’s 100%-owned Clayton Valley Lithium Project in Nevada. Exploration and development by Cypress discovered a world-class resource of lithium-bearing claystone adjacent to the Albemarle Silver Peak mine, North America’s only lithium brine operation. The size of the resource makes the Clayton Valley Project a premier source that has the potential to impact the supply of lithium for the fast-growing global energy storage battery market.

Clayton Valley Lithium Project, Nevada Claims Map:


cyp_cypress_-_albemarle_properties_map.jpg (1060×706) (cypressdevelopmentcorp.com)

Cypress Development Corp. has approximately 98.7 million shares issued and outstanding.

To find out more about Cypress Development Corp. (TSX-V: CYP), visit our website at www.cypressdevelopmentcorp.com.

CYPRESS DEVELOPMENT CORP.

“Dr. Bill Willoughby”

                                                           

WILLIAM WILLOUGHBY, PhD., PE

Chief Executive Officer

For further information contact myself or:
Don Myers
Cypress Development Corp.
Director, Corporate Communications
Telephone: 604-639-3851
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

Important Milestone in Up-Listing Process

PHOENIX, AZ, Dec. 30, 2020 (GLOBE NEWSWIRE) — Taronis Fuels, Inc., (“Taronis” or “the Company”) (OTCQB: TRNF), a global producer of renewable and socially responsible fuel products, today announced the completion of a 1 for 75 common stock reverse split. The reverse split will take effect at the beginning of trading on December 30, 2020. This reverse split enables us to meet important stock price criteria for potential up-listing to a national exchange.

“This is a critical step in our up-listing process,” commented Scott Mahoney, CEO of Taronis Fuels. “Over the past six months we have worked diligently to position the company in anticipation of a formal eligibility review for up-listing to a national exchange. We are preparing to efficiently move into the up-listing process in the near future, and are hopeful that we have positioned the company to complete that process in a timely manner.”

About Taronis Fuels, Inc.

Taronis Fuels, Inc. is a global producer of renewable and socially responsible fuel products. Our goal is to deliver environmentally sustainable, technology driven alternatives to traditional fossil fuel and carbon-based economy products. We believe our products offer a vastly cleaner solution to legacy acetylene and propane alternatives.

Taronis is also dedicated to providing fundamentally safer solutions to meet the industrial, commercial and residential needs of tomorrow’s global economy. Our products have been rigorously tested and independently validated by global gas authorities as vastly safer than acetylene, the most dangerous industrial gas in use today.

Lastly, we strive to deliver products that offer significant function superiority at a reduced cost to the end consumer. Through these efforts, we support 9 of the 17 United Nations Sustainable Development Goals. For more information, please visit our website at www.taronisfuels.com/

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

Investor Contacts:
Michael Khorassani
[email protected]

VANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.

NP-120 (Ifenprodil)
Idiopathic Pulmonary Fibrosis (IPF) & Chronic Cough Clinical Research Program

• March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough.
• May 6 – Received first ethics approval from the Royal Brisbane & Women’s Hospital, Human Research Ethics Committee.
• July 7 – Began screening patients for suitability at five sites in total that are participating in the study, with three located in Australia and two in New Zealand.
• August 5 – Announced that the first patient had been dosed at the Waikato Hospital located in Hamilton, New Zealand.
• October 13 – Announced that the IPF and chronic cough study reached 25% of its enrollment target.

Ifenprodil
COVID-19 Clinical Research Program

• March 6 – Announced exploring the potential of using Ifenprodil as a novel treatment for COVID-19 based on an independent study that found that Ifenprodil significantly reduced acute lung injury and improved survivability in an animal study with H5N1 infected mice. H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate.
• March 13 – Filed a pre-IND (Investigational New Drug) meeting request with the U.S. Federal Drug Administration (U.S. FDA), initiating formal communications to investigate Ifenprodil in a multinational Phase 2b/3 clinical trial for COVID-19.
• March 19 – Agreed to support an investigator-initiated Phase 2 clinical trial of Ifenprodil for COVID-19 patients in South Korea (subsequently withdrawn due to low patient enrollment).
• March 23 – Awarded the contract to manufacture the Company’s own supply of the active pharmaceutical ingredient for Ifenprodil, to U.S. based Cascade Chemistry. 
• April 22 – Submitted a Clinical Trial Application (CTA) to Health Canada for the Company’s planned multinational Phase 2b/3 COVID-19 study of Ifenprodil. 
• April 29 – Received a No Objection Letter from Health Canada for its CTA.
• May 25 – Submitted an Investigational New Drug (IND) application with the U.S. FDA for its planned multinational Phase 2b/3 COVID-19 study of Ifenprodil.
• June 4 – Received clearance from the U.S. FDA for its IND application.
• June 25 – Received ethics approval from a central institutional review board for U.S. study sites.
• July 16 – Completed a clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, the first active U.S. clinical study site.
• August 5 – Announced enrollment of first patient for its Ifenprodil COVID-19 study.
• August 13 – Announced enrollment of its first patient from the U.S. for its Ifenprodil COVID-19 study.
• October 30 – Announced that at its second review meeting, the Ifenprodil COVID-19 study external Data and Safety Monitoring Board had once again unanimously approved the continuation of the Company’s Ifenprodil COVID-19 study (first approval announced on September 16^th). 
• November 30 – Announced that the final patient had been enrolled in its Ifenprodil COVID-19 study.
• December 15 – Reported, in a descriptive format, positive trending interim data for the Phase 2b part of the Company’s Ifenprodil COVID-19 study.
• December 24 – Announced that the last patient from the Phase 2b part of its Ifenprodil COVID-19 study had completed both the treatment period and two week follow up.

Finance

• February 21 – Closed a non-brokered private placement issuing an aggregate of 18,304,939 Units at the price of CDN$0.085 per Unit, raising gross proceeds of CDN$1,555,919.82. Each Unit was comprised of one Class A common share (a “Share”) and one Share purchase warrant. Each whole warrant will entitle the holder to acquire one additional Share at a price of CDN$0.12 per Share.
• May 13 – Closed a private placement offering of special warrants of the Company and issued 19,605,285 warrants at a price of CDN$0.35 each, for aggregate gross proceeds of approximately CDN$6,861,849.00 (the Company filed a prospectus shortly thereafter to qualify the 19,605,285 special warrants issued, with each special warrant converted into one common share and one common share purchase warrant at $CDN.55). 
• November 16 – Received a refundable tax credit of approximately CDN$600,000 from its clinical research work in Australia, representing 40% of allowable expenses refunded from the Company’s Ifenprodil IPF and chronic cough Phase 2 clinical study, with additional refunds expected.
• December 23 – Exercised its acceleration right under the warrant indenture governing the common share purchase warrants of the Company (issued on November 1, 2019), when the daily volume-weighted average trading price of the common shares of the Company exceeded CDN$0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange.

Advisory & Board Appointments

• February 7 – Appointed Dr. Jacky Smith, Professor of Respiratory Medicine and a leading global scientific expert and clinician in the area of understanding the mechanisms underlying cough in respiratory diseases and the testing of novel anti-tussive therapies to the Company’s Medical and Scientific Advisory Board.
• April 13 – Appointed U.S. Ambassador (Rtd) Howard Gutman, former United States Ambassador to Belgium, to the Company’s newly created Business Advisory Board.
• May 13 – Appointed Christopher J. Moreau, the Company’s CEO, to the board of the directors of the Company.
• October 9 – Appointed Dr. Mark Swaim, a former practicing physician and researcher to the Company’s Medical and Scientific Advisory Board.

“While we have made significant progress this past year aggressively advancing our re-purposed drug compound Ifenprodil, by initiating two Phase 2 clinical trials and accomplishing additional related goals and milestones, we are planning for an even more active 2021,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “I want to thank all of our investors for their shared vision and continued support and wish everyone a happy, safe and hope-filled New Year.”

The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.

About NP-120 (Ifenprodil)

NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

The Company believes Ifenprodil may be able to reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. 

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
[email protected]
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

TUCSON, Ariz., Dec. 30, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease Protection Methods for Detection of Nucleotide Variants.”

The patented technology involves a nuclease protection method using wildtype and variant probes competing for binding to a target nucleic acid molecule, such as messenger RNA, to detect the presence, if any, of a variant nucleotide in the target. The patent, which expires in June 2033, is part of a family of patents and patent applications claiming this method, including U.S. patent number 9,765,385 issued on September 19, 2017.

“We continue to strengthen our intellectual property protection with the addition of this patent in Canada, and previously with a patent in Japan, covering this application of our core technology,” stated John Lubniewski, Chief Executive Officer of HTG. “We consistently seek to vigorously protect, expand and improve upon the uses of our nuclease-protection-based technologies in the U.S. and globally. We now have over 20 patents in this space, including our HTG EdgeSeq method patents.”

About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the patent described in the notification of issuance, the strength of our intellectual property portfolio and the benefits of our nuclease protection method. Words such as “expects,” “intends,” “indicator” “progress towards” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: the risk that the patent described in the notification of issuance may not be issued when expected, or at all; the risk that the patent, if issued, may not provide a basis for commercially viable products, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and the risk that our technology does not perform as intended or expected. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Ashley R. Robinson
Phone: (617) 430-7577
Email: [email protected]

 

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.

A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts

Morphic Therapeutic
Chris Erdman
[email protected]
617.686.1718

Media Contact
Adam Silverstein, Ten Bridge Communications
[email protected]
917.697.9313

VANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the “Company”) is pleased to announce that it has officially launched the RevoluEX Cryptocurrency Exchange ahead of schedule.

RevoluEX Vertical

RevoluEX is the Company’s digital currency exchange permitting RevoluPAY app users to convert major cryptocurrencies directly, including BTC, ETH, LINK, XMR, XRP, XLM, DAI & LTC into Fiat money for instant deposit into their RevoluPAY E-Wallet.

PSD2 licensed RevoluPAY then allows users to immediately transfer the Fiat proceeds to a bank account, use them at over 53M VISA Merchants and +100M ATMs worldwide via their RevoluPAY VISA Card, or purchase goods and services from any of the Company’s multiple revenue verticals. Internationally compliant DCE Huobi processes all real-time cryptocurrency conversions. All consequential Fiat currency flows are processed by RevoluPAY for the DCE affiliates, either for final credit to the registered RevoluPAY app user or, in a bilateral manner, for eventual Huobi affiliates. The Company expects partner user onboarding to gradually commence during the first fortnight of January 2021, with reciprocal promotional campaigns increasing progressively into February and beyond.

Cryptocurrency Exchange

Through today’s launch, the Neobanking functionality of RevoluPAY continues to expand into a cutting-edge financial hub, embracing the current explosive growth of cryptocurrency in combination with one of the world’s most prominent DCE affiliates. The increasing white-label use of RevoluPAY to handle payment flows for this, and other financial sectors should engender shareholder value, declaring the Company’s entrance into the multibillion-dollar cryptocurrency arena.

Links Used in This News Release

RevoluEX Crypto Exchange https://www.revoluex.com/
Huobi https://www.huobi.com/
Huobi Daily Transactions https://nomics.com/exchanges/huobipro-huobi-global

About RevoluPAY®

The Company’s flagship Neobanking technology is RevoluPAY®, the Apple and Android multinational payment app. Conceived entirely in-house, RevoluPAY features proprietary, sector-specific technology of which the resulting source code is the Company’s intellectual property. RevoluPAY’s built-in features include Remittance Payments, Forex, Crypto-to-fiat exchange, Retail and Hospitality payments, Real Estate Payments, pay-as-you-go phone top-ups, Gift Cards & Online Credits, Utility Bill payments, Leisure payments, Travel Payments, etc. RevoluPAY employs blockchain protocols and is squarely aimed at the worldwide multi-billion dollar Open Banking sector and + $595 billion family remittance market. RevoluPAY® is operated by the European wholly-owned subsidiary RevoluPAY EP S.L situated in Barcelona. RevoluPAY is a dual-licensed Canadian FINTRAC and European PSD2 payment institution 6900 under the auspices of E.U. Directive 2015/2366 with EU Passporting. RevoluGROUP Canada Inc. controls five wholly-owned subsidiaries on four continents.

About
RevoluGROUP Canada Inc.
:

RevoluGROUP Canada Inc. is a multi-asset, multidivisional publicly traded Canadian Company deploying advanced technologies in the; Banking, Mobile Apps, Money Remittance, Mobile Phone Top-Ups, EGaming, Healthcare Payments, Esports, Invoice factoring, Online Travel, Vacation Resort, Blockchain Systems, and Fintech app sectors. Click here to read more.

For further information on RevoluGROUP Canada Inc. (TSX-V: REVO), visit the Company’s website at www.RevoluGROUP.com. The Company has approximately 171,645,885 shares issued and outstanding.

RevoluGROUP Canada, Inc.

“Steve Marshall”

______________________
STEVE MARSHALL
CEO

For further information, contact:
RevoluGROUP Canada Inc.
Telephone: (604) 332 5355
Facsimile: (604) 687 3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.